Chromosomal microarray better informs brain tumor diagnosis: Robert Jenkins, M.D., Ph.D.
Robert Jenkins, M.D., Ph.D., explains how Mayo Clinic Laboratories' chromosomal microarray assay outperforms other tests for brain tumor analysis. The microarray aligns with the World Health Organization's latest classification of central nervous system t
Audio is streamed directly from the publisher (media.transistor.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
(00:31)
Could you provide a little bit about yourself and your background?
(02:04)
Could you provide an overview of the chromosomal microarray assay?
(05:49)
Why should the chromosomal microarray assay be used over other available assays, such as FISH?
(08:56)
Does the chromosomal microarray provide good benefits in terms of gain of 7 and loss of 10, and EGFR amplification?
(12:03)
What's the value of utilizing the test alongside a neuro-specific NGS panel, such as Mayo Clinic Laboratories' NONCP panel?
(17:20)
How are the results used in patient care?
(19:41)
Is there anything else you feel it's important to highlight?